Cite

HARVARD Citation

    Verma, N. et al. (n.d.). NCMP-05. RITUXIMAB AS INITIAL THERAPY FOR THE REVERSAL OF MYASTHENIA GRAVIS NEUROTOXICITY CAUSED BY IPILIMUMAB/NIVOLUMAB. Neuro-oncology. p. vi194. [Online]. 
  
Back to record